Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
- Symbol
- TBPH
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $883.70M
- 52 week range
- 13.08 - 21.03
Valuation
- Share price
- $17.03 (close of 2026-09-23)
- P/E (TTM)
- 16.07x
- Price to book
- 3.05x
- Price to free cash flow
- 16.45x
- Enterprise value
- $702.51M
- Book value per share
- $5.58
Price performance
| Period | Change |
|---|
| 1 day | -0.12% |
| 5 days | -0.06% |
| 1 month | +0.12% |
| 3 months | +0.35% |
| 6 months | +15.46% |
| Year to date | -8.98% |
| 1 year | +21.04% |
| 3 years | +86.94% |
| 5 years | +140.20% |
| 10 years | -52.42% |
| All time | -25.83% |
Profitability and growth
- Return on equity
- 35.69%
- Return on invested capital
- -2.10%
- Return on assets
- 21.81%
- Return on capital employed
- -0.81%
- Net margin
- 98.54%
- EBITDA margin
- -1.96%
- Revenue growth
- 66.92%
- Net income growth
- 287.70%
- Free cash flow growth
- 2109.77%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.08%
- Current ratio
- 13.54x
- Net debt to EBITDA
- -2.91x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $107.46M
- EBITDA
- $-2.10M
- Net income
- $105.89M
- Earnings per share
- $2.10
- Research and development
- $37.41M
- Shares outstanding
- 50.32M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $107.46M | - | $105.89M | $2.10 |
| 2024-12-31 | $64.38M | - | $-56.42M | $-1.15 |
| 2023-12-31 | $57.42M | $54.68M | $-55.19M | $-1.00 |
| 2022-12-31 | $51.35M | $38.51M | $872.13M | $11.85 |
| 2021-12-31 | $55.31M | $35.17M | $-199.43M | $-2.87 |
| 2020-12-31 | $71.86M | - | $-278.02M | $-4.46 |
| 2019-12-31 | $73.41M | - | $-236.46M | $-4.25 |
| 2018-12-31 | $60.37M | - | $-215.52M | $-3.99 |
| 2017-12-31 | $15.39M | $9.36M | $-285.40M | $-5.45 |
| 2016-12-31 | $48.65M | $45.75M | $-190.67M | $-4.26 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | - | 98.54% | 35.69% | -2.10% |
| 2024-12-31 | - | -87.63% | -32.14% | -25.03% |
| 2023-12-31 | 95.22% | -96.11% | -25.91% | -25.17% |
| 2022-12-31 | 75.00% | 1698.54% | 197.40% | -46.97% |
| 2021-12-31 | 63.58% | -360.55% | 58.90% | -106.91% |
| 2020-12-31 | - | -386.90% | 91.53% | -99.34% |
| 2019-12-31 | - | -322.08% | 105.64% | -107.90% |
| 2018-12-31 | - | -357.01% | 417.77% | -922.24% |
| 2017-12-31 | 60.81% | -1854.97% | -247.79% | -104.07% |
| 2016-12-31 | 94.05% | -391.94% | -54.44% | -3268.15% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $167.81M | - |
| 2024-12-31 | $37.80M | - |
| 2023-12-31 | $39.55M | - |
| 2022-12-31 | $298.17M | - |
| 2021-12-31 | $89.96M | $616.33M |
| 2020-12-31 | $81.47M | $619.17M |
| 2019-12-31 | $58.06M | $455.04M |
| 2018-12-31 | $378.02M | $454.35M |
| 2017-12-31 | $88.98M | $223.75M |
| 2016-12-31 | $344.71M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $238.50M | $18.48M |
| 2024-12-31 | $-11.87M | $21.39M |
| 2023-12-31 | $-29.48M | $25.37M |
| 2022-12-31 | $-187.56M | $39.73M |
| 2021-12-31 | $-211.26M | $62.06M |
| 2020-12-31 | $-257.02M | $62.98M |
| 2019-12-31 | $-241.37M | $60.45M |
| 2018-12-31 | $-120.11M | $51.31M |
| 2017-12-31 | $-203.46M | $49.15M |
| 2016-12-31 | $-101.12M | $41.17M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
- Consensus EPS estimate
- $0.19
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-05-07 | Mar/2026 | - |
| 2026-03-19 | - | - |
| 2025-11-10 | - | - |
| 2025-08-12 | - | - |
| 2025-05-08 | - | - |
| 2025-02-26 | - | - |
| 2024-11-12 | - | - |
| 2024-08-05 | - | - |
Filings and sources
- Company website
- theravance.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades